Mature healthcare-facing SaaS with 54% Adj EBITDA margin, ~20% FCF yield, Corporate channel +8% offsetting SoHo phase-out (-10%). Q1 2026 beat: EPS $1.52 vs $1.35 consensus (+12.6%). Trades at 6x EV/EBITDA vs ZD/OTEX peer median 7-9x. Leverage 2.5x net debt/EBITDA, 6.5% notes due 2028 are the main pivot. Base FV ~$44/sh, current $35.51, ~+24% upside.
Methodology: Segment-weighted EV/EBITDA on FY26E Adj EBITDA of ~$190M, split ~$130M Corporate (8.0x peer-comp) and ~$60M SoHo (4.0x terminal annuity). Net debt $468M deducted at par; cash $92M restored. Buyback accretion modeled at average $35 cost. Bull/Base/Bear probabilities reflect (a) demonstrated Q1 execution, (b) 6.5% notes still on the balance sheet for 2 more years, and (c) secular fax volume risk. ⚠️ Not investment advice.
| Component | Assumption | USD/share |
|---|---|---|
| Corporate Channel EBITDA | $130M Adj EBITDA FY26E × 8.0x EV/EBITDA | +56.5 |
| SoHo Channel EBITDA | $60M Adj EBITDA FY26E × 4.0x EV/EBITDA (terminal annuity) | +13.0 |
| Cash on balance sheet | $92M cash end Q1 2026 / 18.4M shares | +5.0 |
| Total debt (at par) | $560M ($348M HY 6.5% notes 2028 + $148M TL + $64M revolver) | −30.4 |
| Buyback accretion FY26 | $28M auth remaining ÷ ~$35 = ~0.8M shares retired (~4% of float) | +1.4 |
| SoHo terminal-decline discount | −3% risk haircut on aggregate EV (secular fax volume erosion) | −1.5 |
| Base case FV | Sum: 56.5 + 13.0 + 5.0 − 30.4 + 1.4 − 1.5 ≈ $44.0/sh | ≈ $44.00 |
Moderate short interest reflects structural skepticism on cloud-fax durability and 2028 refinancing risk. Below the >25% squeeze threshold. Buyback velocity (~$70M/yr trail) provides natural counter-pressure on float. No notable insider sales: only routine RSU tax-withholding transactions by CTO ($34.00, 336 sh) and CFO (60 sh) in May 2026.
| Item | FY2023 | FY2024 | FY2025 | Q1 2026 | Guidance FY2026 |
|---|---|---|---|---|---|
| Revenue ($M) | 350.4 | 349.7 | 351.0 | 88.5 | ~355–359 (mid $357) |
| Corporate channel ($M) | ~205 | ~209 | ~223 | 57.5 (+8.2%) | ~240 (+7-8%) |
| SoHo channel ($M) | ~145 | ~141 | ~128 | 31.0 (−9.5%) | ~117 (−9%) |
| Adj EBITDA ($M) | 186.6 | 188.4 | 186.9 | ~47.9 | ~185–190 |
| Adj EBITDA margin | 53.3% | 53.9% | 53.2% | 54.1% | ~52-53% |
| Adj EPS ($) | ~5.40 | ~5.60 | ~5.55 | 1.52 | ~5.50–6.00 (mid 5.75) |
| Net debt / EBITDA | ~2.9x | ~2.7x | ~2.5x | 2.5x | 2.2–2.4x |
| FCF ($M, est.) | ~115 | ~125 | ~128 | ~33 | ~130–140 |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
| Revenue ($M) | 87.1 | 87.8 | 87.9 | 88.2 | 88.5 |
| Adj EBITDA margin % | 52.8% | 53.4% | 53.5% | 53.1% | 54.1% |
| Net income ($M) | 21.2 | 21.7 | 22.5 | 22.8 | 24.7 |
| End-of-period cash ($M) | 62 | 71 | 76 | 75 | 92 |
Business model — cloud fax moat funding the interoperability offensive
Corporate Channel (incl. Harmony) ~$240M FY26E (~67% rev) 🟢 ramping eFax Corporate + Unite + Protect + Conductor + jSign. Healthcare-led (HIPAA/HL7/FHIR), ~102% net retention, FedRAMP High opens federal sales. GM target 80%+; growth engine. SoHo Channel (legacy fax) ~$117M FY26E (~33% rev) 🔴 declining eFax consumer/SMB, MyFax, MetroFax, SRfax. Strategic deprioritization: -9.5% in Q1 2026, recent improvement vs -12 to -14% range. Margin >55%, high cash-conversion annuity. Harmony interoperability (sub-segment) embedded in Corporate 🟡 commercializing Healthcare information exchange platform launched late 2025; bundles HL7/FHIR, fax-to-EHR ingestion, NLP. Cross-sell vector into existing 3M+ fax endpoints.
Legal, regulatory and risk analysis
SWOT analysis
- +54% Adj EBITDA margin — top-quartile across small-cap SaaS
- +~20% FCF yield on market cap; capital returned via buyback ($72M deployed)
- +FedRAMP High + HIPAA/HL7/FHIR moat in healthcare interoperability
- +Net retention ~102% in Corporate channel; 5 consecutive EPS beats
- +Asset-light SaaS with negligible CapEx requirement
- −Net debt 2.5x EBITDA; $348M 6.5% notes due 2028 dominate balance sheet
- −SoHo channel in structural decline (-10%/yr) — 33% of revenue at risk
- −Total revenue near-flat 3 years; growth depends entirely on mix shift
- −Brand recognition limited outside healthcare IT and SMB cloud-fax niches
- →Harmony interoperability platform: cross-sell into 3M+ existing fax endpoints
- →Federal government channel post-FedRAMP High certification
- →2028 refinancing at materially tighter spread if rates decline
- →M&A consolidation in healthcare interoperability fragmented landscape
- !UCaaS bundling (RingCentral, Microsoft Teams) commoditizes secure messaging
- !Rate environment shift adds 100-200 bps to 2028 refinancing cost
- !Healthcare CMS / HIPAA policy shifts that reduce fax mandate
- !Acceleration of SoHo decline beyond -15% would force impairment
Summary by assessment area
- ~$130M FCF, ~20% yield on market cap
- Net leverage 2.5x; deleveraging path intact
- $92M cash; no near-term debt maturities (2028 is the pivot)
- Mix shift to Corporate (67% FY26E) must continue
- Harmony interoperability commercialization is unproven at scale
- SoHo decline manageable if it stays ≤−10%/yr
- Forward P/E 6.2x, EV/EBITDA 6.0x vs peer median 7-9x
- Base FV $44 (+24%); risk/reward asymmetric to the upside
- Buyback + deleveraging compound the equity story
Sources: CCSI Q1 2026 8-K and 10-Q (SEC, May 2026), FY2025 8-K (Feb 2026), DEF 14A 2026, Investor Relations (investor.consensus.com), Yahoo Finance, MarketBeat, Stocktitan, BeyondSPX analysis, BusinessWire press release. Market data — last verified close 2026-06-03: CCSI ~$35.51, market cap ~$653M, 52W: $19.42–$37.30, ~18.4M shares outstanding. Short interest: ~13%. Buyback authorization remaining: $28M of $100M extended to Feb 2028. Analyst consensus target: $37.50 (3 analysts Buy, updated 2026-06-02). ⚠️ This document is for informational purposes only and does not constitute financial or investment advice.